Diagnostic testing confirmed the diagnosis of multiple
myeloma affecting her liver, spleen and bone marrow.
Not exact matches
Multiple
myeloma is a cancer that
affects plasma cells.
«One - size treatment for blood cancer probably doesn't fit all, researchers say: Most multiple
myeloma studies involve people of European descent, but the disease is more likely to
affect African - Americans.»
That trend is problematic considering that African - Americans — the most at - risk population for multiple
myeloma — have different genetics that can
affect how this type of cancer progresses and what kind of targeted therapies are most effective, said Zarko Manojlovic, lead author of the study.
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will
affect cancer cells taken from multiple -
myeloma patients.
In the 1990s the U.S. Food and Drug Administration approved its use in the treatment of both multiple
myeloma (a form of cancer that
affects plasma cells) and the complications of leprosy.
Do Plasma Cells
Affect Hemoglobin and Red Blood Cell Counts in Patients With and Without
Myeloma?
A study led by Helena Jernberg Wiklund, Uppsala University / SciLifeLab, shows how the protein EZH2
affects the development of multiple
myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease.
This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that
affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple
myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.
Each donation helps accelerate finding a cure for leukemia, lymphoma and
myeloma, blood cancers which
affect an estimated 1,290,773 Americans.
However, given that these diseases
affect many organs of the body and Gaucher in particular has a high incidence of certain cancers, including
myeloma, I would suggest that eating the most healthy diet for general health (whole food plant based; scientifically proven) would also be a good idea in these diseases (although I have not seen any studies that say this).
Multiple
myeloma is a rare, malignant plasma cell cancer
affecting the bone marrow and other blood producing organs.
In multiple
myeloma, this M component is found in circulation in the blood and sometimes different organs or bones of the body are also
affected.